Literature DB >> 18444803

Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection.

Fredy Roberto Salazar Gutierrez1, Manoj Mathew Lalu, Flávia Sammartino Mariano, Cristiane Maria Milanezi, Jonathan Cena, Raquel Fernanda Gerlach, Jose Eduardo Tanus Santos, Diego Torres-Dueñas, Fernando Queiróz Cunha, Richard Schulz, João Santana Silva.   

Abstract

The strong inflammatory reaction that occurs in the heart during the acute phase of Trypanosoma cruzi infection is modulated by cytokines and chemokines produced by leukocytes and cardiomyocytes. Matrix metalloproteinases (MMPs) have recently emerged as modulators of cardiovascular inflammation. In the present study we investigated the role of MMP-2 and MMP-9 in T. cruzi-induced myocarditis, by use of immunohistochemical analysis, gelatin zymography, enzyme-linked immunosorbent assay, and real-time polymerase chain reaction to analyze the cardiac tissues of T. cruzi-infected C57BL/6 mice. Increased transcripts levels, immunoreactivity, and enzymatic activity for MMP-2 and MMP-9 were observed by day 14 after infection. Mice treated with an MMP inhibitor showed significantly decreased heart inflammation, delayed peak in parasitemia, and improved survival rates, compared with the control group. Reduced levels of cardiac tumor necrosis factor-alpha, interferon-gamma, serum nitrite, and serum nitrate were also observed in the treated group. These results suggest an important role for MMPs in the induction of T. cruzi-induced acute myocarditis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18444803     DOI: 10.1086/587487

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

Review 1.  Chagas heart disease: report on recent developments.

Authors:  Fabiana S Machado; Linda A Jelicks; Louis V Kirchhoff; Jamshid Shirani; Fnu Nagajyothi; Shankar Mukherjee; Randin Nelson; Christina M Coyle; David C Spray; Antonio C Campos de Carvalho; Fangxia Guan; Cibele M Prado; Michael P Lisanti; Louis M Weiss; Susan P Montgomery; Herbert B Tanowitz
Journal:  Cardiol Rev       Date:  2012 Mar-Apr       Impact factor: 2.644

2.  REGULATION of the EXTRACELLULAR MATRIX INTERACTOME by Trypanosoma cruzi.

Authors:  Tatiana C Cardenas; Candice A Johnson; Siddharth Pratap; Pius N Nde; Vyacheslav Furtak; Yuliya Y Kleshchenko; Maria F Lima; Fernando Villalta
Journal:  Open Parasitol J       Date:  2010

3.  Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.

Authors:  Mohammad A M Ali; Woo Jung Cho; Bryan Hudson; Zamaneh Kassiri; Henk Granzier; Richard Schulz
Journal:  Circulation       Date:  2010-11-01       Impact factor: 29.690

4.  Curcumin treatment provides protection against Trypanosoma cruzi infection.

Authors:  Fnu Nagajyothi; Dazhi Zhao; Louis M Weiss; Herbert B Tanowitz
Journal:  Parasitol Res       Date:  2012-01-04       Impact factor: 2.289

Review 5.  Cardiac matrix: a clue for future therapy.

Authors:  Paras Kumar Mishra; Srikanth Givvimani; Vishalakshi Chavali; Suresh C Tyagi
Journal:  Biochim Biophys Acta       Date:  2013-09-17

6.  IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis.

Authors:  Paulo Marcos da Matta Guedes; Fredy R S Gutierrez; Flavia L Maia; Cristiane M Milanezi; Grace K Silva; Wander R Pavanelli; João S Silva
Journal:  PLoS Negl Trop Dis       Date:  2010-02-16

7.  Importance of TLR2 on hepatic immune and non-immune cells to attenuate the strong inflammatory liver response during Trypanosoma cruzi acute infection.

Authors:  Eugenio Antonio Carrera-Silva; Natalia Guiñazu; Andrea Pellegrini; Roxana Carolina Cano; Alfredo Arocena; Maria Pilar Aoki; Susana Gea
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

8.  Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Eva Nozik-Grayck; Ivan F McMurtry; Masahiko Oka; Masanobu Komatsu; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

Review 9.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease.

Authors:  Fabiana S Machado; Walderez O Dutra; Lisia Esper; Kenneth J Gollob; Mauro M Teixeira; Stephen M Factor; Louis M Weiss; Fnu Nagajyothi; Herbert B Tanowitz; Nisha J Garg
Journal:  Semin Immunopathol       Date:  2012-10-18       Impact factor: 9.623

10.  Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against Chagas disease.

Authors:  Shivali Gupta; Trevor S Silva; Jessica E Osizugbo; Laura Tucker; Heidi M Spratt; Nisha J Garg
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.